Development of an early biomarker for the ovarian liability of selective estrogen receptor modulators in rats

Journal of Steroid Biochemistry and Molecular Biology

Volumn 112, Issue 1-3, 2008, Pages 40-46

  Harris, Heather A ^a   Chennathukuzhi, Vargheese M ^a   Zhang, Xiaochun ^a   Mekonnen, Belew ^a   Jelinsky, Scott A ^a   Schelling, Scott H ^a   Patel, Vikram S ^a   Huselton, Christine ^a   Negahban, Andre ^a   Azam, Farooq ^a   Winneker, Richard C ^a  

^a PFIZER INC   (United States)

Author keywords

Cyp17a1; Estradiol; Ovary; SERM

Indexed keywords

BAZEDOXIFENE; CYTOCHROME P450 17; CYTOCHROME P450 17 A1; GONADORELIN AGONIST; LY 2066948; LY 560212; MESSENGER RNA; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN FUNCTION; CONTROLLED STUDY; DRUG BINDING; FEMALE; GENE EXPRESSION REGULATION; HORMONAL REGULATION; NONHUMAN; OVARY FUNCTION; RAT; UPREGULATION; UTERUS FUNCTION;

ANIMALS; BIOLOGICAL MARKERS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN RECEPTOR ALPHA; FEMALE; NAPHTHALENES; OVARIAN CYSTS; OVARY; PIPERIDINES; RALOXIFENE; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STEROID 17-ALPHA-HYDROXYLASE; UP-REGULATION;

RATTUS;

EID: 55349104441     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2008.08.008     Document Type: Article

References (24)

1. Walker C.L., and Stewart E.A. Uterine fibroids: the elephant in the room. Science 308 (2005) 1589-1592
2. Hompes P.G.A., and Mijatovic V. Endometriosis: the way forward. Gynecological Endocrinology 23 (2007) 5-12
3. Stratton P., Sinaii N., Segars J., Koziol D., Wesley R., Zimmer C., Winkel C., and Nieman L.K. Return of chronic pelvic pain from endometriosis after raloxifene treatment-a randomized controlled trial. Obstetrics & Gynecology 111 (2008) 88-96
4. Jirecek S., Lee A., Pavo I., Crans G., Eppel W., and Wenzl R. Raloxifene prevents the growth of uterine leiomyomas in premenopausal women. Fertility & Sterility 81 (2004) 132-136
5. Palomba S., Orio F., Morelli M., Russo T., Pellicano M., Zupi E., Lombardi G., Nappi C., Panici P.L.B., and Zullo F. Raloxifene administration in premenopausal women with uterine leiomyomas: a pilot study. Journal of Clinical Endocrinology & Metabolism 87 (2002) 3603-3608
6. Palomba S., Orio F., Russo T., Falbo A., Cascella T., Doldo P., Nappi C., Lombardi G., Mastrantonio P., and Zullo F. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas. Human Reproduction 19 (2004) 1308-1314
7. Palomba S., Russo T., Orio F., Tauchmanova L., Zupi E., Panici P.L.B., Nappi C., Colao A., Lombardi G., and Zullo F. Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas a prospective, randomized, single-blind, placebo-controlled clinical trial. Human Reproduction 17 (2002) 3213-3219
8. Komm B.S., Kharode Y.P., Bodine P.V.N., Harris H.A., Miller C.P., and Lyttle C.R. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 146 (2005) 3999-4008
9. Faupel-Badger J.M., Prindiville S.A., Venzon D., Vonderhaar B.K., Zujewski J.A., and Eng-Wong J. Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer. Cancer Epidemiology, Biomarkers & Prevention 15 (2006) 1153-1158
10. Geiser A.G., Hummel C.W., Draper M.W., Henck J.W., Cohen I.R., Rudmann D.G., Donnelly K.B., Adrian M.D., Shepherd T.A., Wallace O.B., McCann D.J., Oldham S.W., Bryant H.U., Sato M., and Dodge J.A. A new selective estrogen receptor modulator with potent uterine antagonist activity, agonist activity in bone, and minimal ovarian stimulation. Endocrinology 146 (2005) 4524-4535
11. Premkumar A., Venzon D.J., Avila N., Johnson D.V., Remaley A.T., Forman M.R., Eng-Wong J., Zujewski J., and Stratton P. Gynecologic and hormonal effects of raloxifene in premenopausal women. Fertility & Sterility 88 (2007) 1637-1644
12. Inal M.M., Incebiyik A., Sanci M., Yildirim Y., Polat M., Pilanci B., Nayki C., and Camuzcuoglu H. Ovarian cysts in tamoxifen-treated women with breast cancer. European Journal of Obstetrics, Gynecology, & Reproductive Biology 120 (2005) 104-106
13. Richardson T.I., Frank S.A., Wang M., Clarke C.A., Jones S.A., Ying B.P., Kohlman D.T., Wallace O.B., Shepherd T.A., Dally R.D., Palkowitz A.D., Geiser A.G., Bryant H.U., Henck J.W., Cohen I.R., Rudmann D.G., McCann D.J., Coutant D.E., Oldham S.W., Hummel C.W., Fong K.C., Hinklin R., Lewis G., Tian H., and Dodgea J.A. Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety. Bioorganic & Medicinal Chemistry Letters 17 (2007) 3544-3549
14. Harris H.A., Bapat A.R., Gonder D.S., and Frail D.E. The ligand binding profiles of estrogen receptors alpha and beta are species dependent. Steroids 67 (2002) 379-384
15. Turner T.T., Johnston D.S., Finger J.N., and Jelinsky S.A. Differential gene expression among the proximal segments of the rat epididymis is lost after efferent duct ligation. Biology of Reproduction 77 (2007) 165-171
16. Long G.G., Cohen I.R., Gries C.L., Young J.K., Francis P.C., and Capen C.C. Proliferative lesions of ovarian granulosa cells and reversible hormonal changes induced in rats by a selective estrogen receptor modulator. Toxicologic Pathology 29 (2001) 403-410
17. Peluso J.J. Morphological and physiologic features of the ovary. In: Mohr U., Dungworth D.C., and Capen C.C. (Eds). Pathobiology of the Aging Rat (1992), ILSI Press, Washington, DC 337-349
18. Attard G., Reid A.H.M., Yap T.A., Raynaud F., Dowsett M., Settatree S., Barrett M., Parker C., Martins V., Folkherd E., Clark J., Cooper C.S., Kaye S.B., Dearnaley D., Lee G., and de Bono J.S. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Journal of Clinical Oncology 26 (2008) 4563-4571
19. Taniguchi F., Couse J.F., Rodriguez K.F., Emmen J.M.A., Poirier D., and Korach K.S. Estrogen receptor-alpha mediates an intraovarian negative feedback loop on thecal cell steroidogenesis via modulation of Cyp17a1 (cytochrome P450, steroid 17 alpha-hydroxylase/17,20 lyase) expression. FASEB Journal 21 (2007) 586-595
20. Couse J.F., Yates M.M., Walker V.R., and Korach K.S. Characterization of the hypothalamic-pituitary-gonadal axis in estrogen receptor (ER) null mice reveals hypergonadism and endocrine sex reversal in females lacking ER alpha but not ER beta. Molecular Endocrinology 17 (2003) 1039-1053
21. Schomberg D.W., Couse J.F., Mukherjee A., Lubahn D.B., Sar M., Mayo K.E., and Korach K.S. Targeted disruption of the estrogen receptor-alpha gene in female mice: characterization of ovarian responses and phenotype in the adult. Endocrinology 140 (1999) 2733-2744
22. Couse J.F., Bunch D.O., Lindzey J., Schomberg D.W., and Korach K.S. Prevention of the polycystic ovarian phenotype and characterization of ovulatory capacity in the estrogen receptor-alpha knockout mouse. Endocrinology 140 (1999) 5855-5865
23. Cohen I.R., Tepper R., Figer A., Flex D., Shapira J., and Beyth Y. Successful co-treatment with LHRH-agonist for ovarian over-stimulation and cystic formation in premenopausal tamoxifen exposure. Breast Cancer Research and Treatment 55 (1999) 119-125
24. Hummel C.W., Geiser A.G., Bryant H.U., Cohen I.R., Dally R.D., Fong K.C., Frank S.A., Hinklin R., Jones S.A., Lewis G., McCann D.J., Rudmann D.G., Shepherd T.A., Tian H.Q., Wallace O.B., Wang M.M., Wang Y., and Dodge J.A. A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats. Journal of Medicinal Chemistry 48 (2005) 6772-6775